Clinical Trial Update: Acthar on Proteinuria in IgA Nephropathy Patients [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating Acthar for proteinuria in IgA nephropathy has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• Acthar (repository corticotropin injection)

Snippet

Sponsor: Baylor College of Medicine | Conditions: IgA Nephropathy, Proteinuria | Phase 4 | Status: WITHDRAWN